Stay updated on Pediatric Fosaprepitant Combo for Nausea Clinical Trial
Sign up to get notified when there's something new on the Pediatric Fosaprepitant Combo for Nausea Clinical Trial page.

Latest updates to the Pediatric Fosaprepitant Combo for Nausea Clinical Trial page
- CheckyesterdayChange DetectedThe site footer now identifies the ClinicalTrials.gov release as v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check8 days agoChange DetectedThe record describes a pediatric study of fosaprepitant plus ondansetron for preventing chemotherapy-induced nausea and vomiting, including its design, eligibility criteria, and outcome measures. It also identifies the study as terminated and no longer recruiting.SummaryDifference55%

- Check15 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0; the page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA dismissible NIH notice about website changes and terminology was added above the 403 error page. The displayed site revision changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check43 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check57 days agoChange DetectedA 403 Forbidden error page is now displayed, replacing the previous study content. This indicates the page is currently inaccessible due to permission settings.SummaryDifference19%

Stay in the know with updates to Pediatric Fosaprepitant Combo for Nausea Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pediatric Fosaprepitant Combo for Nausea Clinical Trial page.